Cargando…
Patterns of Medication Prescription among Children and Adolescents with Attention-Deficit/Hyperactivity Disorder in the United States
The objectives of this study are to: (1) quantify the difference in the annual number of prescription medications (total and unique) between children and adolescents with ADHD and those without ADHD; and (2) identify the most prescribed medication classes and unique medications among children and ad...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870051/ https://www.ncbi.nlm.nih.gov/pubmed/35204892 http://dx.doi.org/10.3390/children9020171 |
_version_ | 1784656644040294400 |
---|---|
author | Meraya, Abdulkarim M. |
author_facet | Meraya, Abdulkarim M. |
author_sort | Meraya, Abdulkarim M. |
collection | PubMed |
description | The objectives of this study are to: (1) quantify the difference in the annual number of prescription medications (total and unique) between children and adolescents with ADHD and those without ADHD; and (2) identify the most prescribed medication classes and unique medications among children and adolescents with ADHD. A retrospective cross-sectional study design was employed using data from the 2015 and 2017 Medical Expenditure Panel Survey. The study sample comprised children and adolescents (5–17 years). In the 5–12-year age group, those with ADHD were 2.4%, 17%, and 15% significantly more likely to have one, 2–4, and ≥5 prescription medications, respectively. Similarly, those in the 13–17-year age group were more likely to have one prescription medication (3%), 2–4 prescription medications (15%), and ≥5 prescription medications (12%) than those without ADHD. The most prescribed medications among children and adolescents with ADHD were methylphenidate and amphetamine-dextroamphetamine. ADHD was associated with both higher annual total and unique prescription medications. Additionally, concurrent use of prescription medications was more prevalent among children and adolescents with ADHD. High-quality randomized clinical trials on the safety and efficacy of combinations of multiple psychotherapeutics and stimulants’ agents are required to guide the evidence-based practices. |
format | Online Article Text |
id | pubmed-8870051 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88700512022-02-25 Patterns of Medication Prescription among Children and Adolescents with Attention-Deficit/Hyperactivity Disorder in the United States Meraya, Abdulkarim M. Children (Basel) Article The objectives of this study are to: (1) quantify the difference in the annual number of prescription medications (total and unique) between children and adolescents with ADHD and those without ADHD; and (2) identify the most prescribed medication classes and unique medications among children and adolescents with ADHD. A retrospective cross-sectional study design was employed using data from the 2015 and 2017 Medical Expenditure Panel Survey. The study sample comprised children and adolescents (5–17 years). In the 5–12-year age group, those with ADHD were 2.4%, 17%, and 15% significantly more likely to have one, 2–4, and ≥5 prescription medications, respectively. Similarly, those in the 13–17-year age group were more likely to have one prescription medication (3%), 2–4 prescription medications (15%), and ≥5 prescription medications (12%) than those without ADHD. The most prescribed medications among children and adolescents with ADHD were methylphenidate and amphetamine-dextroamphetamine. ADHD was associated with both higher annual total and unique prescription medications. Additionally, concurrent use of prescription medications was more prevalent among children and adolescents with ADHD. High-quality randomized clinical trials on the safety and efficacy of combinations of multiple psychotherapeutics and stimulants’ agents are required to guide the evidence-based practices. MDPI 2022-01-30 /pmc/articles/PMC8870051/ /pubmed/35204892 http://dx.doi.org/10.3390/children9020171 Text en © 2022 by the author. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Meraya, Abdulkarim M. Patterns of Medication Prescription among Children and Adolescents with Attention-Deficit/Hyperactivity Disorder in the United States |
title | Patterns of Medication Prescription among Children and Adolescents with Attention-Deficit/Hyperactivity Disorder in the United States |
title_full | Patterns of Medication Prescription among Children and Adolescents with Attention-Deficit/Hyperactivity Disorder in the United States |
title_fullStr | Patterns of Medication Prescription among Children and Adolescents with Attention-Deficit/Hyperactivity Disorder in the United States |
title_full_unstemmed | Patterns of Medication Prescription among Children and Adolescents with Attention-Deficit/Hyperactivity Disorder in the United States |
title_short | Patterns of Medication Prescription among Children and Adolescents with Attention-Deficit/Hyperactivity Disorder in the United States |
title_sort | patterns of medication prescription among children and adolescents with attention-deficit/hyperactivity disorder in the united states |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870051/ https://www.ncbi.nlm.nih.gov/pubmed/35204892 http://dx.doi.org/10.3390/children9020171 |
work_keys_str_mv | AT merayaabdulkarimm patternsofmedicationprescriptionamongchildrenandadolescentswithattentiondeficithyperactivitydisorderintheunitedstates |